The aim of this study was to describe the effects of sodium‐glucose co‐transporter 2
(SGLT2) inhibitors on serum uric acid (SUA) in patients with type 2 diabetes mellitus (T2DM) …

To describe the effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric
acid (SUA) in patients with type 2 diabetes mellitus (T2DM). PubMed, EMBASE, and …

Aims The present study aims to determine the effects of sodium‐glucose cotransporter 2
(SGLT‐2) inhibitors on the serum uric acid (SUA) levels of patients with type 2 diabetes …

Objectives: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been found to reduce
serum urate in patients with type 2 diabetes mellitus. To evaluate if this effect applies to both …

Results In the Renoprotective Effects of Dapagliflozin in Type 2 Diabetes study, compared
with the fasted state (5.3±1.1 mg/dl), acute hyperinsulinemia and hyperglycemia significantly …

ABSTRACT Sodium glucose cotransporter 2 (SGLT2) inhibitors have been reported to lower
the serum uric acid (SUA) level. To elucidate the mechanism responsible for this reduction …

Sodium/glucose co‐transporter‐2 (SGLT2) inhibitors, which lower blood glucose by
increasing renal glucose elimination, have been shown to reduce the risk of adverse …

Objective Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for
the treatment of diabetes. We aimed at describing the maximal benefits and risks associated …

This study was conducted to investigate the effects of sodium-glucose cotransporter 2
(SGLT2) inhibitors on individual renal outcomes in patients with type 2 diabetes. We …

Aims To evaluate the mid long-term efficacy and safety of sodium–glucose cotransporter 2
(SGLT2) inhibitors in adults with type 2 diabetes mellitus (T2DM). Methods Three databases …